The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 22, 2021

Filed:

Apr. 09, 2018
Applicant:

Apellis Pharmaceuticals, Inc., Crestwood, KY (US);

Inventors:

Federico Grossi, Newton, MA (US);

Pascal Deschatelets, Lexington, MA (US);

Cedric Francois, Prospect, KY (US);

Patrick Johnson, Zurich, CH;

Carolina Vega, Berkeley, CA (US);

Assignee:

Apellis Pharmaceuticals, Inc., Waltham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 7/00 (2006.01); A61P 37/06 (2006.01); A01N 1/02 (2006.01); A61K 9/00 (2006.01); A61M 5/142 (2006.01); A61M 5/145 (2006.01); A61M 5/152 (2006.01); C07K 7/08 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/60 (2017.08); A01N 1/0226 (2013.01); A61K 9/0019 (2013.01); A61K 47/643 (2017.08); A61K 47/6901 (2017.08); A61M 5/1452 (2013.01); A61M 5/14248 (2013.01); A61M 5/152 (2013.01); A61P 7/00 (2018.01); A61P 37/06 (2018.01); C07K 7/08 (2013.01); A61K 38/00 (2013.01);
Abstract

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.


Find Patent Forward Citations

Loading…